They evaluated methylated septin 9 (mSEPT9) levels in 26 CRC patients undergoing chemotherapy (XELOX, FOLFOX, FOLFIRI), finding that 61.5% showed a decrease post-treatment, while 38.5% had increased levels. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.